Our objective was then to test the effect of CAI, a calcium inhibitor used in clinical trials, on Mcl-1 expression and to evaluate its ability to sensitize ovarian carcinoma cells to anti-Bcl-xL strategies. This evidence concerns the gene MCL1 and ovarian carcinoma.